Gregg Gilbert
Stock Analyst at Truist Securities
(2.29)
# 2,593
Out of 4,862 analysts
91
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $12.15 | +39.92% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $29.18 | +26.80% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $49.75 | +68.84% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $819.36 | -35.93% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $9.93 | +30.92% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $17.55 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $81.71 | +13.82% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $13.43 | +257.41% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $0.76 | +3,313.42% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.84 | +17,757.14% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $26.65 | +192.68% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $164.33 | -52.53% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $16.99 | +5.94% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $112.50 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $108.50 | +61.29% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $191.08 | -65.46% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $12.15
Upside: +39.92%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $29.18
Upside: +26.80%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $49.75
Upside: +68.84%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $819.36
Upside: -35.93%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $9.93
Upside: +30.92%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $17.55
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $81.71
Upside: +13.82%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $13.43
Upside: +257.41%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $0.76
Upside: +3,313.42%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.84
Upside: +17,757.14%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $26.65
Upside: +192.68%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $164.33
Upside: -52.53%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $16.99
Upside: +5.94%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $112.50
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $108.50
Upside: +61.29%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $191.08
Upside: -65.46%